Use of 2′-Spirocyclic Ethers in HCV Nucleoside Design
摘要:
Conformationally restricted 2'-spironucleosides and their prodrugs were synthesized as potential anti-HCV agents. Although the replicon activity of the new agents containing pyrimidine bases was modest, the triphosphate of a 2'-oxetane cytidine analogue demonstrated potent intrinsic biochemical activity against the NS5B polymerase, with IC50 = 8.48 mu M. Activity against NS5B bearing the S282T mutation was reduced. Phosphoramidate prodrugs of a 2'-oxetane 2-amino-6-O-methylpurine nucleoside demonstrated potent anti-HCV activity in vitro, and the corresponding triphosphate retained similar potent activity against both wild-type and S282T HCV NS5B polymerase.
2'-SPIRO-NUCLEOSIDES FOR USE IN THE THERAPY OF HEPATITIS C
申请人:Gilead Pharmasset LLC
公开号:EP3042910A2
公开(公告)日:2016-07-13
Disclosed herein are 2'-spiro-nucleosides of formula I and derivatives thereof useful for treating a subject infected by hepatitis C virus or dengue virus,
wherein
B is selected from among B2 and B3 represented by the following structures:
本文公开了式 I 的 2'-spiro-nucleosides 及其衍生物,可用于治疗丙型肝炎病毒或登革热病毒感染者、
其中
B 选自以下结构代表的 B2 和 B3: